Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi therapeutic platform, announced today that its Board of Directors has appointed Patricia A. Bradford as an independent director of the Company.
“We are delighted to welcome Patricia to the Phio Board. I am certain that her wealth of experience as an executive at rapidly growing international conglomerates and in HR management will bring tremendous value to the Board,” said Robert Bitterman, Chairman of Phio Pharmaceuticals. “We believe that Patricia will be an effective steward of the Company and counselor to the management team.”
Ms. Bradford stated, “I am excited to join the Phio Board at such an important period in the Company’s history, when the first INTASYL therapeutic compounds are entering the clinic this year. I look forward to working with my fellow directors and the Phio management team as the Company’s portfolio of immuno-oncology therapies advance through the clinic in order to treat cancer.”
Ms. Bradford has more than four decades of executive HR experience, as well as a solid financial acumen having obtained CPA accreditation during her time at Deloitte. For more than 30 years of her career, Ms. Bradford held various roles of increasing responsibility at Unisys Corporation. During her last eight years at Unisys, she was the Senior Vice President, Human Resources Officer, reporting directly to the company’s Chief Executive Officer. While in this role she oversaw the strategy and operation of all HR programs on a global basis linked to company goals, which included managing a global HR staff of 200+ employees. Earlier in her career she worked at Deloitte, with positions in the Audit and Tax departments. Currently, Ms. Bradford provides HR consulting services to a wide range of companies focusing on providing individual coaching for senior executives and high potential employees recommended by management.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company’s efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company’s goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company’s website, www.phiopharma.com.
